Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November–December 2022
We tracked the effective reproduction number ( R t ) of the predominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron BF.7 in Beijing in November–December 2022 by fitting a transmission dynamic model parameterized with real-time mobility data to (i) the daily number of...
Gespeichert in:
Veröffentlicht in: | Nature medicine 2023-03, Vol.29 (3), p.579-582 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We tracked the effective reproduction number (
R
t
) of the predominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron BF.7 in Beijing in November–December 2022 by fitting a transmission dynamic model parameterized with real-time mobility data to (i) the daily number of new symptomatic cases on 1–11 November (when China’s zero-COVID interventions were still strictly enforced) and (ii) the proportion of individuals who participated in online polls on 10–22 December and self-reported to have been test-positive since 1 November. After China’s announcement of 20 measures to transition from zero-COVID, we estimated that
R
t
increased to 3.44 (95% credible interval (CrI): 2.82–4.14) on 18 November and the infection incidence peaked on 11 December. We estimated that the cumulative infection attack rate (IAR; that is, proportion of the population infected since 1 November) in Beijing was 75.7% (95% CrI: 60.7–84.4) on 22 December 2022 and 92.3% (95% CrI: 91.4–93.1) on 31 January 2023. Surveillance programs should be rapidly set up to monitor the evolving epidemiology and evolution of SARS-CoV-2 across China.
With the lifting of the zero-COVID policy and requirements governing reporting case numbers in China, it has become imperative to estimate the dynamics and cumulative infection rate of SARS-CoV-2 to help guide public health responses. |
---|---|
ISSN: | 1078-8956 1546-170X |
DOI: | 10.1038/s41591-023-02212-y |